Journal Article

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

van Niekerk, Anika M., Gomme, Emily, Kwatra, Gaurav, Jose, Lisa, Barnabas, Shaun L., Strehlau, Renate, Absalon, Judith, Newton, Ryan, Radley, David, Said, Mohamed, Jefferies, Zahra, Simon, Raphael, Madhi, Shabir A., Izu, Alane, Silmon de Monerri, Natalie C., Fairlie, Lee, Naidoo, Niree, Pavliakova, Danka, Jongihlati, Babalwa, Anderson, Annaliesa S., Munson, Samantha, Jansen, Kathrin U., Jones, Stephanie, Perez, John L., Gruber, William C., Ramsamy, Yogandree, Scott, Daniel A.

2023

Overview

Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants. In an ongoing phase 2, placebo-controlled trial involving pregnant women, we assessed the safety and immunogenicity of a single dose of various GBS6 formulations and analyzed maternally transferred anti-CPS antibodies. In a parallel seroepidemiologic study that was conducted in the same population, we assessed serotype-specific anti-CPS IgG concentrations that were associated with a reduced risk of invasive disease among newborns through 89 days of age to define putative protective thresholds. Naturally acquired anti-CPS IgG concentrations were associated with a reduced risk of disease among infants in the seroepidemiologic study. IgG thresholds that were determined to be associated with 75 to 95% reductions in the risk of disease were 0.184 to 0.827 μg per milliliter. No GBS6-associated safety signals were observed among the mothers or infants. The incidence of adverse events and of serious adverse events were similar across the trial groups for both mothers and infants; more local reactions were observed in the groups that received GBS6 containing aluminum phosphate. Among the infants, the most common serious adverse events were minor congenital anomalies (umbilical hernia and congenital dermal melanocytosis). GBS6 induced maternal antibody responses to all serotypes, with maternal-to-infant antibody ratios of approximately 0.4 to 1.3, depending on the dose. The percentage of infants with anti-CPS IgG concentrations above 0.184 μg per milliliter varied according to serotype and formulation, with 57 to 97% of the infants having a seroresponse to the most immunogenic formulation. GBS6 elicited anti-CPS antibodies against group B streptococcus in pregnant women that were transferred to infants at levels associated with a reduced risk of invasive group B streptococcal disease. (Funded by Pfizer and the Bill and Melinda Gates Foundation; C1091002 ClinicalTrials.gov number, NCT03765073.).

• Publisher: Massachusetts Medical Society
• Subject: Adverse events / Age / Aluminum / Antibiotics / Antibodies / Antibodies, Bacterial / Babies / Bacterial Infections / Capsular polysaccharides / Childbirth & labor / Childhood Diseases / Complications of Pregnancy / Congenital defects / Consent / Design / Disease prevention / Female / Global Health / Gynecology / Gynecology General / Hernia / Humans / Immunity, Maternally-Acquired - immunology / Immunization / Immunogenicity / Immunoglobulin G / Infant / Infant, Newborn / Infants / Infectious Disease / Infectious Disease General / Neonates / Neonatology / Newborn babies / Obstetrics / Pediatrics / Pediatrics General / Pregnancy / Premature labor / Review boards / Risk assessment / Seroepidemiologic Studies / Serotypes / Streptococcal Infections - epidemiology / Streptococcal Infections - immunology / Streptococcal Infections - prevention & control / Streptococcal Vaccines - administration & dosage / Streptococcal Vaccines - adverse effects / Streptococcal Vaccines - immunology / Streptococcal Vaccines - therapeutic use / Streptococcus / Streptococcus agalactiae / Streptococcus infections / Vaccines / Vaccines, Combined - administration & dosage / Vaccines, Combined - adverse effects / Vaccines, Combined - immunology / Vaccines, Combined - therapeutic use / Vaccines, Conjugate - administration & dosage / Vaccines, Conjugate - adverse effects / Vaccines, Conjugate - immunology / Vaccines, Conjugate - therapeutic use / Vagina / Womens health